CN103599211B - A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof - Google Patents
A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN103599211B CN103599211B CN201310525364.7A CN201310525364A CN103599211B CN 103599211 B CN103599211 B CN 103599211B CN 201310525364 A CN201310525364 A CN 201310525364A CN 103599211 B CN103599211 B CN 103599211B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- diabetes
- treatment
- lazurite
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 54
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 51
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 25
- 241001230539 Spiraea alpina Species 0.000 claims abstract description 24
- 239000011347 resin Substances 0.000 claims abstract description 24
- 229920005989 resin Polymers 0.000 claims abstract description 24
- 241001096899 Ferula ammoniacum Species 0.000 claims abstract description 22
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 claims abstract description 22
- 229910052667 lazurite Inorganic materials 0.000 claims abstract description 22
- 239000006187 pill Substances 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 17
- 239000012567 medical material Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000012467 final product Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- -1 reflux Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 22
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 230000005180 public health Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XVVBVBKVMMNZHB-LFYBBSHMSA-N 9-[(e)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]furo[3,2-g]chromen-7-one Chemical compound C=12OC=CC2=CC=2C=CC(=O)OC=2C=1OC\C=C(/C)CC1OC(=O)C(C)=C1 XVVBVBKVMMNZHB-LFYBBSHMSA-N 0.000 description 2
- 229910017121 AlSiO Inorganic materials 0.000 description 2
- 241000133570 Berberidaceae Species 0.000 description 2
- 241001518358 Berberis nummularia Species 0.000 description 2
- 241000365446 Cordierites Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000125183 Crithmum maritimum Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 244000259229 Grindelia squarrosa Species 0.000 description 2
- 235000005717 Grindelia squarrosa Nutrition 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 241001362861 Lepisorus clathratus Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 241000196124 Polypodiaceae Species 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001506047 Tremella Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004760 silicates Chemical group 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof, it is characterized in that: this medicine is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 2-5 part, Dorema ammoniacum resin 3-5 part, Spiraea alpina 1-4 part, mesh Herba Lepisori Thunbergiani 3-8 part, lazurite 1-3 part.Above-mentioned each crude drug pulverized 80 order-200 mesh sieves, made pill etc., or was prepared from through extracting.Drug regimen of the present invention has good using value to treatment diabetes.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
Background technology
Along with the aging of world population, diabetes have become a kind of commonly encountered diseases, frequently-occurring disease, and in industrially developed country, its sickness rate is in rising trend.According to statistics, about there are 1.5 hundred million diabeticss in the whole world, and 80% is non-insulin-dependent diabetes mellitus (2 type), and wherein China about has 3,000 ten thousand.The death toll caused by diabetic complication has been the rank rear the 3rd of cardiovascular and cerebrovascular disease, cancer of continuing in developed country, causes the great attention of countries in the world, studies one after another to the pathogenesis, medical treatment etc. of diabetes.Because the type 1 diabetes cause of disease is substantially clear and definite, only need supplementation with insulin, type 2 diabetes mellitus is then more complicated, and what current China medical circle was taked it is the complex treatment measure comprising dietetic therapy, Drug therapy and other complementary therapy.Although Western medicine emerges in an endless stream, can not tackle the problem at its root, and western medicine has certain side effect and " failure in treatment ".TCM Treatment of Diabetes is with a long history, and clinical experience enriches, evident in efficacy, has become recent domestic study hotspot.The understanding of Chinese medicine to diabetes is different from doctor trained in Western medicine, and the traditional Chinese medical science emphasizes Overall View, with the essence of the change of both yin, yangs reflection disease.Normal body is " YIN and YANG in a relative equilibrium ", equilibrium between yin and yang, and namely organismic internal environment maintains stable state, and carbohydrate metabolism also remains stable; And the toxic and side effects of Chinese medicine is relatively little, patient can long-term taking, and this is the advantage of the uniqueness that Western medicine can not be compared.
The traditional Chinese medical science thinks that diabetes to be burnt cloudy losing by lung, stomach, the dirty heat of kidney three, water paddy transfer not normal caused by.Its base
This pathogenesis is cloudy body fluid deficiency consumption, scorching inclined Sheng, and deficiency of kidney-YIN is originally, and lung dryness of the stomach heat is mark, sick then cloudy damage QI consumed sun wound of a specified duration, and causes impairment of both QI and YIN, deficiency in both YIN and YANG, venation block, and the mistake of muscle arteries and veins is supported, and internal organs are impaired, gradually causes a series of double disease of appearance.
The course of disease of diabetes is processes of deficiency of YIN affecting YANG.Dialectical with the moon, from gently to heavy, be then the conversion of the deficiency of YIN-deficiency of both QI and YIN-deficiency of both YIN and YANG.And venation block is through the overall process of primary disease and double disease.
In recent years, some scholars have inquired into the relation of TCM Syndrome Differentiation of Diabetes and clinical biochemistry indications.From changes such as islet function, blood lipid level, sexual hormones, corticoid level, immunologic function machine hemorheologys, the dependency that observation diabetes typing and above index change, find the ANOMALOUS VARIATIONS of various index, from gently to heavy, how with the deficiency of YIN-deficiency of both QI and YIN-deficiency of both YIN and YANG future development.Embody the material base that diabetes typing is inquired in the combination of Chinese and Western medicine.
Determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is the marrow of theory of Chinese medical science.The traditional Chinese medical science, according to the main pathogenesis of diabetes, distinguishes specimen weight that the is scorching and deficiency of YIN, payes attention to yin nourishing during medication, has scorching person then must heat clearing away, and yang blood and qi all loses, then yang blood and qi mending.According to modern pharmacology concept, mainly as follows to Chinese medicine diabetes Effect study.Single medicinal material: Rhizoma Coptidis and berberine, Fructus Momordicae charantiae, Radix Ginseng, the Radix Astragali, Radix Scutellariae, Folium Mori, herbal polysaccharide (as tremella polysaccharide, tremella polysaccharide spore, Auricularia polysaccharide, Hericium erinaceus polysaccharide, Porphyra Polysaccharide, Radix Ophiopogonis polysaccharide, laminaran (laminarin), lycium barbarum polysaccharide-X, lycium barbarum polysaccharide-D, Fructus Caricae polysaccharide and Cortex Moutan polysaccharide etc.), silymarin, Radix Et Rhizoma Rhei.In addition, oral administration of flavonoids puerarin (puerarin) or clausenacoumarine (clausenacoumarine) hyperglycemia to ALX animal also have reducing effect.The basic principle of TCM treatment of diabetes can be summarized as: nourishing YIN and clearing away heat, supplementing QI and nourishing YIN, kidney and spleen invigorating and blood circulation promoting and blood stasis dispelling etc.Conventional classic prescriptions has Ginseng Baihu Decoction, LIUWEI DIHUANG WAN, eight Dihuang Wans and a thousand pieces of gold coptis teeta pill etc., according to different pattern of syndrome and above-mentioned rule for the treatment of prescription or add and subtract with ancient prescription.
Radix Berberidis Amurensis fruit is the dry mature fruit of Berberidaceae plant Berberis nummularia Bge. BerberisnummulariaBge..Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle ".Its property put down, have stomach invigorating and in, promoting the production of body fluid to quench thirst, effect of heat-clearing and toxic substances removing.For dyspepsia, under dysentery is rushed down, thirsty, aphtha, pharyngitis.
Dorema ammoniacum resin is the resin of samphire Ammonia grindelia DoremaammoniacumD.Don..The end of spring and the beginning of summer full-bloom stage is to the first fruit phase, and incised wound cervical region, collects the lactescence natural gum oozed out, dry in the shade.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle ".There is cold expelling gas, dry cold-damp, softening the hard mass relieving constipation, take out and let out body deep layer abnormal humour, open effect of liver spleen impatency.For cold arthralgia, ankylosis, skin is firmly swollen, oxter and Neck lymphatic tuberculosis, chronic cough abundant expectoration, lusterless complexion.
Spiraea alpina is dried floral, the leaf of rosaceous plant Spiraea alpina SpiraeaalpinaTurcz..Florescence gathers, and dries.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China mongolian medicine fascicle " cool in nature, sweet in the mouth.Have bone heat clearly, promote the production of body fluid, hemostasis, holds back effect of yellow fluid.For controlling skin infection, grasserie, ascites, pulmonary congestion, metrorrhagia.
Mesh Herba Lepisori Thunbergiani is the dried leaves of Plants of Polypodiaceae mesh Herba Lepisori Thunbergiani Lepisorusclathratus (Clarke) Ching.Record in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) ", standard number: WS3-BC-0036-95.It is cool in nature, bitter in the mouth, has more skin ulcer, cheesy pus, arresting seminal emission, Gu bone marrow, heat-clearing and toxic substances removing, connects the effect of mending skull.For splanchnocoel disease, burn, lumbago due to damp-heat.The common drug of the minority areas such as illiteracy is hidden for China.But about the basic research of mesh Herba Lepisori Thunbergiani is still very limited, the follow-up promotion and application of this medical material are restricted.Modern study shows, mesh Herba Lepisori Thunbergiani contains chlorogenic acid and ecdysterone and the flavone compound such as Quercetin, kaempferol, and other chemical compositions are not quite clear; Pharmacological action has no report.
Lazurite is silicates mineral cordierites, main containing Na
6ca [AlSiO
4]
6(SO
4, Cl, S)
2.After excavating, removing silt and assorted stone.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle ".Have removing abnormal humour, the burning of control body fluid, control abnormal savda produces, treating blood disorders of nourishing heart, logical stagnant effect of stimulating the menstrual flow.Vexed for melancholy, restlessness, the weak blood resistance of the heart, amenorrhea cough with asthma.
Namely existing document and patent etc., there is not yet Chinese medicine composition of the present invention: the compositions of Radix Berberidis Amurensis fruit, Dorema ammoniacum resin, Spiraea alpina, mesh Herba Lepisori Thunbergiani, lazurite composition is for the preparation of the report for the treatment of diabetes medicament.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
The present invention is achieved through the following technical solutions:
The present invention is raw materials used
Radix Berberidis Amurensis fruit is the dry mature fruit of Berberidaceae plant Berberis nummularia Bge. BerberisnummulariaBge..Dorema ammoniacum resin is the resin of samphire Ammonia grindelia DoremaammoniacumD.Don..Spiraea alpina is dried floral, the leaf of rosaceous plant Spiraea alpina SpiraeaalpinaTurcz..Mesh Herba Lepisori Thunbergiani is the dried leaves of Plants of Polypodiaceae mesh Herba Lepisori Thunbergiani Lepisorusclathratus (Clarke) Ching.Lazurite is silicates mineral cordierites, main containing Na
6ca [AlSiO
4]
6(SO
4, Cl, S)
2.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 2-5 part, Dorema ammoniacum resin 3-5 part, Spiraea alpina 1-4 part, mesh Herba Lepisori Thunbergiani 3-8 part, lazurite 1-3 part.
Preferred compositions proportioning: a kind of pharmaceutical composition for the treatment of diabetes of the present invention, is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3 parts, Dorema ammoniacum resin 4 parts, Spiraea alpina 2.5 parts, mesh Herba Lepisori Thunbergiani 6 parts, lazurite 2 parts.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, it is characterized in that preparing as follows: each crude drug was pulverized 80 order-200 mesh sieves, makes powder or tablet or pill or capsule.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, it is characterized in that preparing as follows:
(1) Radix Berberidis Amurensis fruit, Spiraea alpina, mesh Herba Lepisori Thunbergiani, three taste medical materials use water as Extraction solvent, and 70 DEG C-95 DEG C extractions, extraction time is 1-4 time, and each extraction time is 1-4 hour, and each solvent load is 8-15 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A;
(2) Dorema ammoniacum resin, lazurite, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, it is characterized in that preparing as follows:
(1) Radix Berberidis Amurensis fruit, Spiraea alpina, mesh Herba Lepisori Thunbergiani, three taste medical materials use water as Extraction solvent, reflux, extract, and extraction time is 3 times, and each extraction time is 2 hours, and each solvent load is 12 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A;
(2) Dorema ammoniacum resin, lazurite, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
The pharmaceutical composition for the treatment of diabetes of the present invention, the treatment diabetes medicament formed with chemical drugs or Chinese medicine or natural drug.
Pharmaceutical composition provided by the invention, by blood sugar lowering, regulating blood lipid action research, result shows, has remarkable hypoglycemic activity to diabetic mice, can regulate diabetic mice blood lipid level simultaneously.Compare with model group, pharmaceutical composition of the present invention significantly can reduce alloxan and cause blood glucose in diabetic mice value (P<0.05), and significantly can reduce epinephrine and cause blood glucose in diabetic mice value (P<0.05).Administration group mice triacylglycerol, low density lipoprotein, LDL content significantly decline (P<0.05), and hdl concentration significantly raises (P<0.05).
Detailed description of the invention
Treat diabetes medicament composition and method of making the same below by specific experiment example and embodiment to one of the present invention to be described further, but be not limited to the present invention.
Embodiment 1: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3kg, Dorema ammoniacum resin 4kg, Spiraea alpina 2.5kg, mesh Herba Lepisori Thunbergiani 6kg, lazurite 2kg;
Pharmaceutical composition preparation method: each crude drug was pulverized 90 mesh sieves, mixing, adds appropriate water pill, dry, to obtain final product.
Embodiment 2: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 2kg, Dorema ammoniacum resin 5kg, Spiraea alpina 1kg, mesh Herba Lepisori Thunbergiani 8kg, lazurite 1kg;
Pharmaceutical composition preparation method: each crude drug was pulverized 80 mesh sieves, mixing, to obtain final product.
Embodiment 3: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 5kg, Dorema ammoniacum resin 3kg, Spiraea alpina 4kg, mesh Herba Lepisori Thunbergiani 3kg, lazurite 3kg;
Pharmaceutical composition preparation method: each crude drug was pulverized 200 mesh sieves, mixing, makes granule with Diluted Alcohol, dry, adds starch, magnesium stearate, tabletting, to obtain final product.
Embodiment 4: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 4 parts, Dorema ammoniacum resin 2 parts, Spiraea alpina 3 parts, mesh Herba Lepisori Thunbergiani 4.3 parts, lazurite 2.5 parts;
Pharmaceutical composition preparation method: each crude drug was pulverized 100 mesh sieves, mixing, makes granule with Diluted Alcohol, dry, adds magnesium stearate, encapsulated, to obtain final product.
Embodiment 5: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3 parts, Dorema ammoniacum resin 4 parts, Spiraea alpina 2.5 parts, mesh Herba Lepisori Thunbergiani 6 parts, lazurite 2 parts;
Pharmaceutical composition preparation method: (1) Radix Berberidis Amurensis fruit, Spiraea alpina, mesh Herba Lepisori Thunbergiani, three taste medical materials use water as Extraction solvent, reflux, extract, and extraction time is 3 times, and each extraction time is 2 hours, and each solvent load is 12 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A; (2) Dorema ammoniacum resin, lazurite, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
Add customary adjuvant and make various dosage form on pharmaceutics.
Embodiment 6: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3kg, Dorema ammoniacum resin 4kg, Spiraea alpina 2.5kg, mesh Herba Lepisori Thunbergiani 6kg, lazurite 2kg;
Pharmaceutical composition preparation method: (1) Radix Berberidis Amurensis fruit, Spiraea alpina, mesh Herba Lepisori Thunbergiani, three taste medical materials use water as Extraction solvent, and 70 DEG C of extractions, extraction time is 1 time, and each extraction time is 4 hours, and each solvent load is 15 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A; (2) Dorema ammoniacum resin, lazurite, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
Add customary adjuvant and make various dosage form on pharmaceutics.
Embodiment 7: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3kg, Dorema ammoniacum resin 4kg, Spiraea alpina 2.5kg, mesh Herba Lepisori Thunbergiani 6kg, lazurite 2kg;
Pharmaceutical composition preparation method: (1) Radix Berberidis Amurensis fruit, Spiraea alpina, mesh Herba Lepisori Thunbergiani, three taste medical materials use water as Extraction solvent, and 95 DEG C of extractions, extraction time is 4 times, and each extraction time is 1 hour, and each solvent load is 8 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A; (2) Dorema ammoniacum resin, lazurite, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
Add customary adjuvant and make various dosage form on pharmaceutics.
Experimental example 1: pharmaceutical composition blood sugar lowering, regulating blood lipid action.
1. medicine and reagent
The pharmaceutical composition that experimental drug thing is embodiment 1, embodiment 4 prepares, is numbered pharmaceutical composition 1, pharmaceutical composition 4(lot number: 20100822,20100823).Alloxan (Sigma Co., USA); Glucose kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 102401.201010); T-CHOL test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 101051.201007): triacylglycerol test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 104101.201008); High density lipoprotein test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 100361) low density lipoprotein, LDL test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 100271); Glibenclamide (Tianjin Lisheng Pharmaceutical Co., Ltd., lot number: 1003013); All the other agents useful for same are analytical pure.
2. laboratory animal
Kunming mouse, body weight l8-22g, cleaning grade, male and female half and half, are provided by Mountain Western Medicine S University's Experimental Animal Center.It is consistent that this tests all animal feedings, starts to test front 3d and put the raising of this laboratory observation, freely ingest, drink water.Each group of feedstuff is originated all identical with drinking water.
3. instrument
Rotary evaporator RE-52AA (Shanghai Yarong Biochemical Instrument Plant); 752 ultraviolet-uisible spectrophotometers (Shanghai Precision Scientific Apparatus Co., Ltd); Centrifuge LXJ-IIB (Anting Scientific Instrument Factory, Shanghai); Electronic balance BS-124S (Beijing Sai Duolisi instrument system company limited).
4. experimental technique.
4.1 cause the impact of blood glucose in diabetic mice and blood fat to alloxan
The freshly prepared alloxan 50mg/kg of mouse tail vein injection causes diabetes model, after 72h.Fasting be can't help to the mouse orbit rear vein beard blood sampling of water, survey blood glucose value, choose the mice of fasting glucose higher than 11.1mmol/L for experiment.Get qualified model mice 40, be divided into 4 groups at random, glibenclamide group (10), pharmaceutical composition 1, pharmaceutical composition 4 (often organizing each 10), diabetic model group, separately gets the normal mouse of similar weight as normal group (10).After successive administration 14d. before last administration, water 8h is can't help in mice fasting, continue fasting after administration and can't help 2h after water, pluck eyeball and get blood, measure the fasting blood sugar of each group, total cholesterol level, triacylglycerol content, hdl concentration, low density lipoprotein, LDL content.
4.2 cause the impact of blood glucose in diabetic mice to epinephrine
Get qualified Kunming mouse 60 (male and female half and half), be divided into 4 groups at random, pharmaceutical composition 1, pharmaceutical composition 4 (often organizing 10) and glibenclamide group (10) dosage are with " 4.1 ", model group (10) and normal group (10) gavage equal-volume normal saline, successive administration 10d.Before last administration, water 8h is can't help in mice fasting, and continue after fasting can't help water 6h after administration, except matched group, every mouse peritoneal Injection of Adrenaline 0.2mg, Normal group is the capacity normal saline such as lumbar injection then.After 30min, retroorbital venous clump is taken a blood sample, and measures the fasting blood sugar of each group.
4.3 statistical procedures
Experimental data mean ± standard deviation (X ± S) represents, makes t check the significance comparing group difference.
5. result.
5.1 cause the impact of blood glucose in diabetic mice to alloxan
After successive administration 14d, the mouse blood sugar value of pharmaceutical composition 1, pharmaceutical composition 4 all has significance to decline (P<0.05) compared with model group, with glibenclamide group mouse blood sugar value no significant difference (P>0.05), the results are shown in Table 1.
Table 1 pharmaceutical composition is on the impact of alloxan diabetes mouse blood sugar
Note: compare with normal group,
#p<0.05; Compare with model group,
*p<0.05.
5.2 cause the impact of blood glucose in diabetic mice to epinephrine
After administration 10d, lumbar injection adrenalin hydrochloride, model group mouse blood sugar value is significantly higher than normal group (P<0.05); Administration group mouse blood sugar value is all remarkable in model group (P<0.05), does not have significant difference (P>0.05) with glibenclamide group.The results are shown in Table 2.
Table 2 pharmaceutical composition is on the impact of epinephrine blood glucose in diabetic mice
Note: compare with Normal group,
#p<0.05; Compare with model control group,
*p<0.05.
5.3 cause the impact of diabetic mice blood lipid level to alloxan
After administration 14d. compare with normal group, diabetic groups mice TC, TG, LDL-C content significantly raises (P<0.05), and HDL-C content significantly declines (P<0.05); Compare with model group, administration group mice TG, LDL-C content significantly declines (P<0.05), and HDL-C content significantly raises (P<0.05).In table 3.
Table 3 pharmaceutical composition is on the impact of alloxan diabetes lipid of mice
Note: compare with normal group,
#p<0.05; Compare with model group,
*p<0.05.
Result shows: pharmaceutical composition of the present invention has remarkable hypoglycemic activity to diabetic mice, can regulate diabetic mice blood lipid level simultaneously.Compare with model group, pharmaceutical composition of the present invention significantly can reduce alloxan and cause blood glucose in diabetic mice value (P<0.05), and significantly can reduce epinephrine and cause blood glucose in diabetic mice value (P<0.05).Administration group mice triacylglycerol, low density lipoprotein, LDL content significantly decline (P<0.05), and hdl concentration significantly raises (P<0.05).
Claims (5)
1. treat a pharmaceutical composition for diabetes, it is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 2-5 part, Dorema ammoniacum resin 3-5 part, Spiraea alpina 1-4 part, mesh Herba Lepisori Thunbergiani 3-8 part, lazurite 1-3 part.
2. a kind of pharmaceutical composition for the treatment of diabetes according to claim 1, is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 3 parts, Dorema ammoniacum resin 4 parts, Spiraea alpina 2.5 parts, mesh Herba Lepisori Thunbergiani 6 parts, lazurite 2 parts.
3. a kind of pharmaceutical composition for the treatment of diabetes according to claim 1, it is characterized in that preparing as follows: each crude drug was pulverized 80 order-200 mesh sieves, makes powder or tablet or pill or capsule.
4. treat a preparation method for the pharmaceutical composition of diabetes, it is characterized in that preparing as follows:
(1) Radix Berberidis Amurensis fruit 3kg, Spiraea alpina 2.5kg, mesh Herba Lepisori Thunbergiani 6kg, three taste medical materials use water as Extraction solvent, and 70 DEG C-95 DEG C extractions, extraction time is 1-4 time, each extraction time is 1-4 hour, and each solvent load is 8-15 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A;
(2) Dorema ammoniacum resin 4kg, lazurite 2kg, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
5. a kind of preparation method for the treatment of the pharmaceutical composition of diabetes according to claim 4, is characterized in that preparing as follows:
(1) Radix Berberidis Amurensis fruit 3kg, Spiraea alpina 2.5kg, mesh Herba Lepisori Thunbergiani 6kg, three taste medical materials use water as Extraction solvent, reflux, extract, and extraction time is 3 times, and each extraction time is 2 hours, and each solvent load is 12 times of three taste medical material weight; Filter, merge extractive liquid, concentrated, dry, obtain extract A;
(2) Dorema ammoniacum resin 4kg, lazurite 2kg, two taste pulverizing medicinal materials, to fine powder, mix with extract A, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525364.7A CN103599211B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525364.7A CN103599211B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599211A CN103599211A (en) | 2014-02-26 |
| CN103599211B true CN103599211B (en) | 2015-12-30 |
Family
ID=50117517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310525364.7A Active CN103599211B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599211B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108245665A (en) * | 2018-02-22 | 2018-07-06 | 天津中新药业集团股份有限公司隆顺榕制药厂 | Pharmaceutical composition and its preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005325025A (en) * | 2004-05-12 | 2005-11-24 | Green Kanpo Seiyaku Kk | Diabetes-preventing/treating composition |
| CN101269198A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Pure Chinese medicine preparation for preventing and treating enteron disease and improving self phylactic power, and preparation method thereof |
| CN101757074A (en) * | 2009-11-13 | 2010-06-30 | 秦大伟 | Chewable tablet prepared from berberis |
-
2013
- 2013-10-31 CN CN201310525364.7A patent/CN103599211B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005325025A (en) * | 2004-05-12 | 2005-11-24 | Green Kanpo Seiyaku Kk | Diabetes-preventing/treating composition |
| CN101269198A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Pure Chinese medicine preparation for preventing and treating enteron disease and improving self phylactic power, and preparation method thereof |
| CN101757074A (en) * | 2009-11-13 | 2010-06-30 | 秦大伟 | Chewable tablet prepared from berberis |
Non-Patent Citations (1)
| Title |
|---|
| 中医学对糖尿病足的认识及中医特色外治法源流;鞠上等;《中医研究》;20090731;第22卷(第7期);第8-10页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599211A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN102188613B (en) | Traditional Chinese medicine preparation for treating diabetes | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN103749822A (en) | Fructus ligustri lucidi health-care tea for lowering blood pressure and lipid and preparation method thereof | |
| CN103041209A (en) | Chinese herbal preparation for curing deficiency of kidney-yin and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN103749818A (en) | Rhizoma polygonati healthcare tea with hypoglycemic and hypolipidemic effects and preparation method thereof | |
| CN103749819B (en) | Fructus Corni health protection tea of a kind of hypoglycemic and preparation method thereof | |
| CN106362007A (en) | Traditional Chinese medicine composition containing dendrobium huoshanense and achieving glucose lowering effect and preparation method thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN103599211B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN104434941A (en) | Medicine composition for treating diabetes | |
| CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
| CN103463244A (en) | Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance | |
| CN103550505A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency type diabetes | |
| CN103585234B (en) | The application of Radix Berberidis Amurensis berry extract in preparation treatment diabetes medicament | |
| CN103585198B (en) | The preparation method of mesh Herba Lepisori Thunbergiani extract and application thereof | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN103585312B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN105079451A (en) | Blood-glucose-reducing blueberry tea and preparation method thereof | |
| CN103585302B (en) | The application of the extracts such as a kind of Song Sheng in preparation treatment diabetes medicament | |
| CN103585205B (en) | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament | |
| CN108478745A (en) | One seed ginseng Chinese herbaceous peony nourishing qi and blood particle Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Liyun Inventor after: Li Dongmei Inventor after: Fengjinyan Inventor after: Han Chuanping Inventor after: Zhang Yanli Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151104 Address after: 266000 No. 9 Huangpu Road, first people's Hospital, Qingdao Development Zone, Shandong, China Applicant after: Wang Liyun Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Liyun Inventor after: Li Dongmei Inventor after: Fengjinyan Inventor after: Han Chuanping Inventor after: Zhang Yanli Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160322 Address after: 266000 No. 9 Huangpu Road, first people's Hospital, Qingdao Development Zone, Shandong, China Patentee after: Wang Liyun Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Patentee before: Ji'nan Star Medical Technology Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Shao Chenglei Document name: Notification of Passing Examination on Formalities |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170711 Address after: 226500 Rugao City, Jiangsu province Gao Ding Yan Zhen Village 42 groups Patentee after: Rugao Fu friend hospital Address before: 266000 No. 9 Huangpu Road, first people's Hospital, Qingdao Development Zone, Shandong, China Patentee before: Wang Liyun |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191121 Address after: 313000 1-C, building 1, No. 656, Qixing Road, high tech Zone, Wuxing District, Huzhou City, Zhejiang Province Patentee after: Huzhou xinbeilian Network Technology Co.,Ltd. Address before: 226500 the 42 groups of Gao Nan village, Dingyan Town, Rugao, Jiangsu Patentee before: Rugao Fu friend hospital |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191223 Address after: No. 200, companion Kun Road, Minhang District, Shanghai Patentee after: Shanghai Pukang Pharmaceutical Co.,Ltd. Address before: 313000 1-C, building 1, No. 656, Qixing Road, high tech Zone, Wuxing District, Huzhou City, Zhejiang Province Patentee before: Huzhou xinbeilian Network Technology Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating diabetes and its preparation method Effective date of registration: 20230627 Granted publication date: 20151230 Pledgee: Bank of Hangzhou Limited by Share Ltd. Shanghai branch Pledgor: Shanghai Pukang Pharmaceutical Co.,Ltd. Registration number: Y2023310000315 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20151230 Pledgee: Bank of Hangzhou Limited by Share Ltd. Shanghai branch Pledgor: Shanghai Pukang Pharmaceutical Co.,Ltd. Registration number: Y2023310000315 |